PBD Biotech has closed a seed investment round through contributions from Anglia Capital Group and Cambridge Agritech to launch its proprietary Mycobacterial detection technology. The company uses phage technology for rapid detection of live bacteria with high sensitivity and specificity in animal tissues.
PBD Biotech closes oversubscribed seed investment round
PBD Biotech Ltd is delighted to announce that it has successfully completed an over-subscribed seed investment round composed of angel investment from Cambridge Agritech Ltd and Anglia Capital Group. Previously, the Company had initiated its activities based on funding from the University of Nottingham Governance board and a grant received from the Greater Cambridge Greater Peterborough LEP’s Eastern Agri-Tech Growth Initiative to support its innovative technology for rapid, accurate and sensitive diagnosis of bacterial infection in animals.
Terms of the investment were not disclosed but Dr Berwyn Clarke (CEO) commented that “the investment will allow the company to further develop its manufacturing requirements and to progress its global commercialisation activities that are already attracting significant interest from many parts of the world”.
For further information please visit www.pbdbio.com
PBD Biotech specialises in novel phage-based diagnostic technology in the field of veterinary diagnostics.